Harvard Bioscience (NASDAQ:HBIO) Price Target Raised to $7.50

Harvard Bioscience (NASDAQ:HBIO) had its target price boosted by equities research analysts at Benchmark from $6.00 to $7.50 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “speculative buy” rating on the medical instruments supplier’s stock. Benchmark’s price target suggests a potential upside of 22.35% from the stock’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.75.

Harvard Bioscience Stock Performance

Shares of Harvard Bioscience stock opened at $6.13 on Wednesday. Harvard Bioscience has a 12 month low of $3.75 and a 12 month high of $9.40. The firm has a market capitalization of $27.65 million, a P/E ratio of -2.82 and a beta of 1.49. The company has a current ratio of 1.99, a quick ratio of 1.06 and a debt-to-equity ratio of 3.60. The business has a fifty day simple moving average of $6.15 and a two-hundred day simple moving average of $5.82.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $22.73 million during the quarter, compared to analyst estimates of $21.45 million. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%.

Hedge Funds Weigh In On Harvard Bioscience

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 11,948 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Harvard Bioscience in the fourth quarter worth $26,000. Legato Capital Management LLC raised its stake in shares of Harvard Bioscience by 210.4% in the fourth quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 29,462 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Harvard Bioscience by 291.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 37,057 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new position in shares of Harvard Bioscience during the fourth quarter valued at $38,000. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Harvard Bioscience

Here are the key news stories impacting Harvard Bioscience this week:

• Positive Sentiment: Second-quarter revenue increased 11% year over year to $22.7 million, above the $21.45 million analyst consensus. Adjusted EBITDA rose to $1.7 million from $1.5 million, and adjusted EPS of negative $0.14 beat expectations of negative $0.21. Harvard Bioscience Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $89.1 million-$90.9 million, versus the prior consensus of $88.6 million, implying 3%-5% growth. It also expects full-year adjusted EBITDA growth of 6%-10%. Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance
• Positive Sentiment: The company highlighted Project Viking, a strategic transformation aimed at strengthening its focus on translational science. Recent insider activity was also supportive, with executives and directors making purchases and no reported sales during the past six months. Harvard Bioscience Advances Transformation with Project Viking Launch
• Neutral Sentiment: Third-quarter revenue guidance of $21.0 million-$22.6 million brackets the $21.9 million consensus, suggesting limited near-term upside despite the stronger full-year forecast.
• Negative Sentiment: GAAP net loss widened to $2.9 million, or approximately $0.14 per share, from $2.3 million a year earlier. Gross margin was 55.6%, while management expects product and geographic mix, including CMT and China, to move future gross margin toward 57%-59%. Harvard Bioscience targets 2026 revenue growth
• Negative Sentiment: The company’s continuing losses, negative profitability metrics and highly leveraged balance sheet may be tempering enthusiasm over the earnings beat. The mixed institutional activity—eight investors added shares while 40 reduced positions—also signals limited conviction.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.